Evidence map›Paper›PMID 22885357›Full record

ArticleMolecules (Basel, Switzerland)2012

In vitro and in vivo antitumor effect of trachylobane-360, a diterpene from Xylopia langsdorffiana.

João Carlos Lima Rodrigues Pita, Aline Lira Xavier, Tatyanna Kelvia Gomes de Sousa, Vivianne Mendes Mangueira, Josean Fechine Tavares, Robson José de Oliveira Júnior, Robson Cavalcante Veras, Hilzeth de Luna Freire Pessoa, Marcelo Sobral da Silva, Sandra Morelli and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

João Carlos Lima Rodrigues PitaLaboratory of Pharmaceutical Technology, Federal University of Paraíba, P.O. Box 5009, João Pessoa 58051-970, PB, Brazil. joaocpita@yahoo.com.br
Aline Lira Xavier
Tatyanna Kelvia Gomes de Sousa
Vivianne Mendes Mangueira
Josean Fechine Tavares
Robson José de Oliveira Júnior
Robson Cavalcante Veras
Hilzeth de Luna Freire Pessoa
Marcelo Sobral da Silva
Sandra Morelli
Veridiana de Melo Rodrigues Ávila
Teresinha Gonçalves da Silva
Margareth de Fátima Formiga Melo Diniz
Marianna Vieira Sobral Castello-Branco
Universidade Federal da Paraíba · BRUniversidade Federal de Uberlândia · BRUniversidade Federal de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trachylobane-360 (ent-7α-acetoxytrachyloban-18-oic acid) was isolated from Xylopia langsdorffiana. Studies have shown that it has weak cytotoxic activity against tumor and non-tumor cells. This study investigated the in vitro and in vivo antitumor effects of trachylobane-360, as well as its cytotoxicity in mouse erythrocytes. In order to evaluate the in vivo toxicological aspects related to trachylobane-360 administration, hematological, biochemical and histopathological analyses of the treated animals were performed. The compound exhibited a concentration-dependent effect in inducing hemolysis with HC₅₀ of 273.6 µM, and a moderate in vitro concentration-dependent inhibitory effect on the proliferation of sarcoma 180 cells with IC₅₀ values of 150.8 µM and 150.4 µM, evaluated by the trypan blue exclusion test and MTT reduction assay, respectively. The in vivo inhibition rates of sarcoma 180 tumor development were 45.60, 71.99 and 80.06% at doses of 12.5 and 25 mg/kg of trachylobane-360 and 25 mg/kg of 5-FU, respectively. Biochemical parameters were not altered. Leukopenia was observed after 5-FU treatment, but this effect was not seen with trachylobane-360 treatment. The histopathological analysis of liver and kidney showed that both organs were mildly affected by trachylobane-360 treatment. Trachylobane-360 showed no immunosuppressive effect. In conclusion, these data reinforce the anticancer potential of this natural diterpene.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicBody WeightCell SurvivalDiterpenesDose-Response Relationship, DrugFemaleHematologic TestsHemolysisInhibitory Concentration 50MiceOrgan SizeSarcoma 180Transplantation, HomologousTumor BurdenXylopiaAntineoplastic Agents, PhytogenicDiterpenesent-7alpha-acetoxytrachyloban-18-oic acid

Identifiers

PMID22885357
PMCPMC6269042
OpenAlexW2007413492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.